1921
Volume 76, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

16α-Bromoepiandrosterone (HE2000) is a synthetic androstane steroid that has immune effects in pre-clinical models of malaria, tuberculosis, and infection with human immunodeficiency virus. In pilot studies, 42 patients with confirmed uncomplicated malaria were treated with a seven-day course of HE2000 by either buccal administration or intramuscular injection. Of the 42 patients, 41 showed a 50% reduction in blood levels of parasites, the primary endpoint of the study. Of these, 32 (76%) cleared malaria parasites below detectable levels. All febrile patients became afebrile by the end of treatment. There was no reduction in gametocyte forms. Adverse events were transient and mild to moderate in intensity. The anti-malarial response was generally similar with either the intramuscular or buccal routes of administration. HE2000 shows a safety profile and pharmacologic activity worthy of further investigation to understand its role in the treatment of malaria, perhaps in combination with anti-malarial agents.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2007.76.232
2007-02-01
2018-12-11
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/2/0760232.html?itemId=/content/journals/10.4269/ajtmh.2007.76.232&mimeType=html&fmt=ahah

References

  1. Milhous WK, Kyle DE, 1998. Introduction to the modes of action of and mechanisms of resistance to antimalarials. Sherman IW, ed. Malaria: Parasite Biology, Pathogenesis, and Protection. Washington, DC: American Society for Microbiology Press, 303–316.
  2. Peters W, 1987. Chemotherapy and Drug Resistance in Malaria. New York: Academic Press, 145–273.
  3. Danis M, Bricaire F, 2003. The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria. Fundam Clin Pharmacol 17 : 155–160. [Google Scholar]
  4. Loria RM, Padgett DA, 1992. Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol 127 : 103–115. [Google Scholar]
  5. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W, 1988. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 26 : 301–314. [Google Scholar]
  6. Padgett DA, Loria RM, Sheridan JF, 1997. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol. J Neuroimmunol 78 : 203–211. [Google Scholar]
  7. Daigle J, Carr DJ, 1998. Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production. J Immunol 160 : 3060–3066. [Google Scholar]
  8. Pedersen NC, North TW, Rigg R, Reading C, Higgins J, Leutenegger C, Henderson GL, 2003. 16alpha-bromoepiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Vet Immunol Immunopathol 94 : 133–148. [Google Scholar]
  9. Hernandez Pando R, Aguilar Leon D, Orozco H, Serrano A, Ahlem C, Trauger R, Schramm B, Reading C, Frincke J, Rook GAW, 2005. 16α-bromoepiandrosterone restores T helper cell Type 1 activity and accelerates chemotherapy-induced bacterial clearance in model of progressive pulmonary tuberculosis. J Infect Dis 191 : 299–306. [Google Scholar]
  10. Ben-Nathan D, Padgett DA, Loria RM, 1999. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J Med Microbiol 48 : 425–431. [Google Scholar]
  11. Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, McKinney L, Miner VL, Jackson WE, Loria RM, Ledney GD, Seed TM, 2000. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int J Immunopharmacol 22 : 1–14. [Google Scholar]
  12. Freilich D, Ferris S, Wallace M, Leach L, Kallen A, Frincke J, Ahlem C, Hacker M, Nelson D, Hebert J, 2000. 16alpha-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth. Am J Trop Med Hyg 63 : 280–283. [Google Scholar]
  13. Rasmussen KR, Healey MC, 1992. Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters. J Parasitol 78 : 554–557. [Google Scholar]
  14. Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimasarn K, 2001. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 32 : 41–49. [Google Scholar]
  15. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva: World Health Organization.
  16. Agresti A, 2002. Statistical Inference for Binomial Parameters. Categorical Data Analysis. New York: Wiley-Interscience, 14–21.
  17. Reading C, Dowding C, Schramm B, Garsd A, Onizuka-Handa N, Stickney D, Frincke J, 2006. Improvement in immune parameters and HIV-1 viral response in individuals treated wtih 16alpha-bromoepiandrosterone (HE2000). Clin Microbiol Infect 12 : 1082–1088. [Google Scholar]
  18. Spellberg B, Edwards JE Jr, 2001. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 32 : 76–102. [Google Scholar]
  19. Taylor-Robinson AW, 1998. Immunoregulation of malarial infection: balancing the vices and virtues. Int J Parasitol 28 : 135–148. [Google Scholar]
  20. Malaguarnera L, Imbesi RM, Pignatelli S, Simpore J, Malaguarnera M, Musumeci S, 2002. Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite Immunol 24 : 387–389. [Google Scholar]
  21. Torre D, Speranza F, Giola M, Matteelli A, Tambini R, Biondi G, 2002. Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clin Diagn Lab Immunol 9 : 348–351. [Google Scholar]
  22. Musumeci M, Malaguarnera L, Simpore J, Messina A, Musumeci S, 2003. Modulation of immune response in Plasmodium falciparum malaria: role of IL-12, IL-18 and TGF-beta. Cytokine 21 : 172–178. [Google Scholar]
  23. Serghides L, Kain KC, 2001. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol 166 : 6742–6748. [Google Scholar]
  24. White NJ, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18 : 458–464. [Google Scholar]
  25. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV, 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69 : 558–563. [Google Scholar]
  26. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ, 2001. Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 45 : 2897–2901. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.232
Loading
/content/journals/10.4269/ajtmh.2007.76.232
Loading

Data & Media loading...

  • Received : 13 Dec 2005
  • Accepted : 20 Oct 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error